Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 11/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7664074 | 0.99 | ADRA1A (0.47) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7662754 | 0.99 | ADRA1A (0.47) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7662174 | 0.90 | ADRA1A (0.51) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL8003105 | 0.85 | ADRA1A (0.44) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7662448 | 0.84 | OPRM1 (0.53) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7662404 | 0.84 | OPRM1 (0.50) | ADRA1AADRA1DADRA1BOPRM1 | |
| Hydrochloric Acid SCHEMBL7660460 | 0.83 | OPRM1 (0.52) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7668015 | 0.83 | OPRM1 (0.52) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7664062 | 0.83 | OPRM1 (0.49) | ADRA1AADRA1DADRA1BOPRM1 | |
| SCHEMBL7655701 | 0.83 | ADRA1A (0.47) | ADRA1AADRA1DADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6339090-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-01-15 | — | — | US | claimed |
| US-6228870-B1 | BENIGN PROSTATIC HYPERPLASIA; REDUCTION OF HYPOTENSION SIDE EFFECT | MERCK & CO., INC. | 2001-05-08 | — | — | US | claimed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6339090-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-01-15 | — | — | US | disclosed |
| US-6319932-B1 | USEFUL FOR TREATING BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-11-20 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6235759-B1 | BENIGN PROSTATIC HYPERPLASIA; HYPOTENSIVE AGENTS | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| US-6228870-B1 | BENIGN PROSTATIC HYPERPLASIA; REDUCTION OF HYPOTENSION SIDE EFFECT | MERCK & CO., INC. | 2001-05-08 | — | — | US | disclosed |
| WO-2000025782-A1 | DIHYDROPYRIDINONES AND PYRROLINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | ADRA1A 4/4885ADRA1D 3/4885ADRA1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.